PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL

por Liu, X.-D., Liang, Y.-Z., Piao, Y.-S., Wang, L.
Publicado 2022

P1153: LONG-TERM SURVIVAL OUTCOMES OF PATIENTS WITH PRIMARY OCULAR ADNEXAL MALT LYMPHOMA: A LARGE SINGLE-CENTER COHORT STUDY

por Liang, Y., Fu, R.-Y., Li, X., Piao, Y.-S., Ma, J.-M., Wang, L.
Publicado 2022

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First‐Line Gastric Cancer and Elevated Plasma VEGF‐A

por Han, K, Claret, L, Piao, Y, Hegde, P, Joshi, A, Powell, JR, Jin, J, Bruno, R
Publicado 2016